HCVAVERT
Partnership to cure hepatitis C virus (HCV) in mono- and HIV/HCV co-infected pregnant women and prevent VERTical HCV transmission.
A preparatory study for strategic planning and design of future trials to cure hepatitis C virus in pregnant women and prevent vertical HCV transmission.
What is this study about?
The World Health Organization (WHO) has an ambitious plan to eliminate hepatitis C (HCV) by 2030, but no treatment is available for pregnant women, constituting an important gap and making eradication unlikely. Pregnancy is an opportunity to screen and diagnose HCV, but it is not known whether treatment during pregnancy is safe and if it prevents vertical HCV transmission.
As part of HCVAVERT, we are conducting a detailed feasibility study for a trial in Egypt and Ukraine and exploring other countries with high prevalence of HCV. With collaborating partners at Bristol University and INSERM, we are conducting meta-analyses and modelling of the timing of vertical transmission and exploring the cost effectiveness of screening and treatment strategies in pregnant women.
Type of study
Meta-analyses
Who is funding the study?
MRC Global Health Trials
When is it taking place?
1st July 2018 for 18 months
Where is it taking place?
Ukraine and Egypt
Who is included?
Pregnant women with hepatitis C and their infants